12:54 PM EDT, 06/06/2025 (MT Newswires) -- Phathom Pharmaceuticals ( PHAT ) shares jumped nearly 104% in recent Friday trading after the company said the US Food and Drug Administration approved its citizen petition to grant full New Chemical Entity exclusivity for its acid-reducing drug, Voquezna, or vonoprazan.

The FDA confirmed it will update the Orange Book to reflect a corrected 10-year exclusivity period for Voquezna tablets, now extending through May 3, 2032.

Phathom filed the petition on Dec. 11, 2024, to correct the exclusivity duration for Voquezna, which is approved to treat erosive esophagitis and Helicobacter pylori infections, the biopharmaceutical company said.

Price: 9.57, Change: +4.88, Percent Change: +103.94